ERBB2 and breast cancer: Moreover, the development of novel antibodies, including bispecific antibodies andantibody-drug conjugates, holds promise in further enhancing the efficacy oftargeted therapies for HER2-positive BC [22].Bispecific antibodies, such as trastuzumab deruxtecan (T-DXd; DS-8201), cansimultaneously target HER2-positive tumor cells and immune cells, promotingimmune-mediated cytotoxicity and enhancing anti-tumor responses [23].